Canadian (TSX) Biotech Industry Analysis
UpdatedApr 21, 2024
DataAggregated Company Financials
Companies29
- 7D-5.5%
- 3M-1.7%
- 1Y-37.2%
- YTD-8.2%
Over the last 7 days, the Biotech industry has dropped 5.5%, driven by Medicenna Therapeutics declining 16%. The industry has fallen 37% in the last year. Looking forward, earnings are forecast to grow by 37% annually.
Industry Valuation and Performance
Has the Canadian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 21 Apr 2024 | CA$874.3m | CA$79.5m | -CA$301,685,064.26 | 12.6x | -2.9x | 11x |
| Tue, 19 Mar 2024 | CA$1.1b | CA$91.6m | -CA$320,217,123.81 | 11.1x | -3.6x | 12.4x |
| Thu, 15 Feb 2024 | CA$1.1b | CA$87.2m | -CA$323,735,872.77 | 10.4x | -3.3x | 12.4x |
| Sat, 13 Jan 2024 | CA$3.6b | CA$86.2m | -CA$516,247,702.00 | 6.8x | -6.9x | 41.3x |
| Mon, 11 Dec 2023 | CA$3.8b | CA$86.1m | -CA$543,138,347.00 | 5.6x | -6.9x | 43.7x |
| Wed, 08 Nov 2023 | CA$3.8b | CA$88.9m | -CA$542,970,944.00 | 7.8x | -6.9x | 42.2x |
| Fri, 06 Oct 2023 | CA$3.8b | CA$89.0m | -CA$526,162,468.00 | 6.1x | -7.3x | 43x |
| Sun, 03 Sep 2023 | CA$4.0b | CA$90.0m | -CA$513,801,240.00 | 6.1x | -7.8x | 44.7x |
| Tue, 01 Aug 2023 | CA$4.0b | CA$81.9m | -CA$515,977,162.00 | 7.2x | -7.8x | 48.9x |
| Thu, 29 Jun 2023 | CA$4.0b | CA$86.4m | -CA$549,244,562.00 | 13x | -7.2x | 46x |
| Sat, 27 May 2023 | CA$3.8b | CA$86.9m | -CA$608,188,765.00 | 11.1x | -6.3x | 43.9x |
| Mon, 24 Apr 2023 | CA$3.7b | CA$83.8m | -CA$598,401,888.00 | 12.3x | -6.2x | 44.6x |
| Wed, 22 Mar 2023 | CA$2.6b | CA$90.4m | -CA$620,392,824.00 | 9.3x | -4.3x | 29.3x |
| Fri, 17 Feb 2023 | CA$2.9b | CA$89.1m | -CA$589,658,227.00 | 8.6x | -4.9x | 32.7x |
| Sun, 15 Jan 2023 | CA$3.1b | CA$87.5m | -CA$525,283,764.00 | 11.6x | -5.8x | 34.9x |
| Tue, 13 Dec 2022 | CA$3.3b | CA$88.6m | -CA$579,676,215.00 | 7.1x | -5.6x | 36.8x |
| Thu, 10 Nov 2022 | CA$3.1b | CA$86.0m | -CA$566,604,054.00 | 14.8x | -5.4x | 35.6x |
| Sat, 08 Oct 2022 | CA$3.1b | CA$86.1m | -CA$549,676,132.00 | 14.7x | -5.7x | 36.4x |
| Mon, 05 Sep 2022 | CA$3.6b | CA$84.6m | -CA$537,622,667.00 | 13x | -6.7x | 42.7x |
| Wed, 03 Aug 2022 | CA$3.3b | CA$87.3m | -CA$563,558,453.00 | 11.3x | -5.8x | 37.6x |
| Fri, 01 Jul 2022 | CA$3.1b | CA$181.2m | -CA$609,994,015.00 | 11.5x | -5.1x | 17.3x |
| Sun, 29 May 2022 | CA$3.2b | CA$179.4m | -CA$606,213,701.00 | 15.6x | -5.2x | 17.7x |
| Tue, 26 Apr 2022 | CA$3.4b | CA$176.4m | -CA$491,566,556.00 | 14.3x | -6.9x | 19.2x |
| Thu, 24 Mar 2022 | CA$3.2b | CA$170.7m | -CA$490,742,226.00 | 13.9x | -6.6x | 19x |
| Sat, 19 Feb 2022 | CA$3.5b | CA$168.0m | -CA$455,384,834.00 | 17.3x | -7.7x | 20.8x |
| Mon, 17 Jan 2022 | CA$3.4b | CA$166.4m | -CA$429,998,987.00 | 19.6x | -7.9x | 20.3x |
| Wed, 15 Dec 2021 | CA$5.9b | CA$165.3m | -CA$494,744,660.00 | 10.1x | -12x | 35.9x |
| Fri, 12 Nov 2021 | CA$6.1b | CA$172.2m | -CA$449,880,289.00 | 7.2x | -13.5x | 35.2x |
| Sun, 10 Oct 2021 | CA$7.9b | CA$240.5m | -CA$608,032,848.00 | 8.1x | -13.1x | 33x |
| Tue, 07 Sep 2021 | CA$8.1b | CA$222.8m | -CA$562,923,623.08 | 7.2x | -14.5x | 36.5x |
| Thu, 05 Aug 2021 | CA$3.5b | CA$161.7m | -CA$474,887,008.08 | 26.8x | -7.4x | 21.7x |
| Sun, 09 May 2021 | CA$4.4b | CA$154.4m | -CA$492,315,138.31 | 16x | -8.9x | 28.3x |
Price to Earnings Ratio
-8.9x
Current Industry PE
- Investors are pessimistic on the Canadian Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 32.1x is higher than the industry's current PS ratio of 11.0x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 20% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Trends
Which industries have driven the changes within the Canadian Healthcare industry?
| CA Market | -0.59% | |
| Healthcare | -1.68% | |
| Biotech | -5.49% | |
| Biotech | -5.49% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| METX ME Therapeutics Holdings | CA$3.72 | 3.0% +CA$2.6m | n/a | n/a | |
| CHGX ChitogenX | CA$0.065 | 62.5% +CA$2.1m | -61.8% | PE-1.7x | |
| TTI Thiogenesis Therapeutics | CA$0.79 | 5.3% +CA$1.8m | 14.5% | PB10.5x | |
| KNE Kane Biotech | CA$0.14 | 8.0% +CA$1.3m | 8.0% | PS119.5x | |
| MSCL Satellos Bioscience | CA$0.52 | 2.0% +CA$1.1m | -11.9% | PB1.4x |